Log In Sign up
The largest database of trusted experimental protocols

Viread

Manufactured by Gilead Sciences
Visit Supplier
Sourced in United States

Viread is a nucleotide reverse transcriptase inhibitor (NtRTI) used in the treatment of HIV-1 infection. It contains the active ingredient tenofovir disoproxil fumarate, which interferes with the activity of the HIV reverse transcriptase enzyme, a crucial component in the HIV replication process.

Automatically generated - may contain errors

Lab products found in correlation

Kaletra, by Abbott (1 mentions) Vemlidy, by Gilead Sciences (1 mentions) Atripla, by Bristol-Myers Squibb (1 mentions) Truvada, by Gilead Sciences (1 mentions) Emtriva, by Gilead Sciences (1 mentions) Sustiva, by Bristol-Myers Squibb (1 mentions) Tenofovir, by Gilead Sciences (1 mentions)

5 protocols using viread

1

Delamanid and antiretroviral therapy study

Check if the same lab product or an alternative is used in the 5 most similar protocols
Delamanid tablets were manufactured by Otsuka Pharmaceutical Co., Ltd. (Japan). Tenofovir was supplied as commercially available Viread manufactured by Gilead Sciences, Inc. (Foster City, CA), and lopinavir/ritonavir was supplied as commercially available Kaletra manufactured by Abbott Laboratories (Abbott Park, IL). Subjects were randomly assigned to receive one of the five following treatments for 14 days: 100 mg of delamanid (two 50-mg tablets) twice daily, 300 mg of tenofovir (one 300-mg Viread tablet) once daily, 300 mg of tenofovir once daily plus 100 mg of delamanid twice daily, 400 mg of lopinavir and 100 mg of ritonavir (two 200/50-mg Kaletra tablets) twice daily, or 400 mg of lopinavir and 100 mg of ritonavir twice daily plus 100 mg of delamanid twice daily. All doses were given orally with 240 ml of room temperature still water. The once-daily dose or the morning dose of the twice-daily regimens was given within 30 min of the start of a standard meal. The evening dose of twice-daily regimens was given 12 h after the morning dose and within 30 min after the start of a standard meal.
Mallikaarjun S., Wells C., Petersen C., Paccaly A., Shoaf S.E., Patil S, & Geiter L. (2016). Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 60(10), 5976-5985.
+ Open protocol
+ Expand
2

Maternal TAF vs. TDF for CHB

Check if the same lab product or an alternative is used in the 5 most similar protocols
All mothers with active CHB were orally administered a dose of 25 mg TAF (Vemlidy; Gilead Sciences, Foster City, CA) or 300 mg TDF (Viread; Gilead Sciences, Foster City, CA) daily and were therefore divided into 2 groups, the TAF group and the TDF group. The TAF and TDF selections were based on the pregnant women's personal or their family's preferences (Supplementary Methods).
Zeng Q.L., Zhang H.X., Zhang J.Y., Huang S., Li W.Z., Li G.M., Pan Y.J., Feng Y.H., Li Z.Q., Zhang G.F., Xu J.H., Lin W.B., Xu G.H., Liu N., Zhang G.Q., Li G.T., Li W., Zeng Y.L., Song N., Wang M., Zhang D.W., Chen Z.M., Cui G.L., Li J., Lv J., Liu Y.M., Liang H.X., Sun C.Y., Zhou Y.H., Yu Z.J, & Wang F.S. (2022). Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 20(12).
+ Open protocol
+ Expand
3

HBV Hepatitis Therapy Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The protocol was approved by the HBRN Steering Committee and the Institutional Review Boards (Research Ethics Board in the case of the Canadian site) of the participating sites, and all participants provided written informed consent. The study was overseen by an independent data safety monitoring board (DSMB) appointed by the NIDDK to monitor the clinical studies of the HBRN. TDF (Viread ® ) was kindly provided by Gilead Sciences, Foster City, CA, PegIFN-alfa2a (Pegasys ® ) by Roche Genentech, San Francisco, CA, and assays for HBV DNA by Roche Diagnostics, Indianapolis, IN, but these entities had no role in study design, data collection, data analysis or interpretation or the writing of this report.
Terrault N.A., Lok A.S., Wahed A.S., Ghany M.G., Perrillo R.P., Fried M.W., Wong D.K., Khalili M., Lau D.T.Y., Sterling R.K., Di Bisceglie A.M., Lisker-Melman M., Cooper S.L., Chung R.T., Patel K., Roberts L.R., Belle S.H, & Janssen H.L.A. (2023). Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. The American journal of gastroenterology, 118(7).
+ Open protocol
+ Expand
4

Bioequivalence Criteria for ARV Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
The acceptable reference products for emtricitabine, tenofovir, lamivudine and efavirenz in single formulation or FDCs for demonstrating bioequivalence are as follows: Emtriva ® (emtricitabine) 200 mg capsule, Gilead Sciences; Viread ® (tenofovir disoproxil fumarate) 300 mg tablet, Gilead Sciences; Epivir ® (lamivudine) 150 mg and 300 mg tablet, GlaxoSmithKline; Sustiva ® (efavirenz) 100 mg and 200 mg capsule, 600 mg tablet Bristol-Myers Squibb; Truvada ® (tenofovir disoproxil fumarate/emtricitabine) 300/200 mg tablet, Gilead Sciences; and Atripla ® (tenofovir disoproxil fumarate/efavirenz/emtricitabine) 300/600/200 mg tablet, Bristol-Myers Squibb and Gilead Sciences.
Gwaza L., Gordon J., Welink J., Potthast H., Leufkens H., Stahl M, & García-Arieta A. (2017). Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons. Antiviral therapy, 22(2).
+ Open protocol
+ Expand
5

Evaluation of Tenofovir Adherence in HBsAg-Positive Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
HBsAg-positive individuals who attended the liver clinic were assessed for eligibility for treatment in accordance with the 2012 European Association for the Study of the Liver (EASL) guidelines 19 (appendix p 3). In the absence of contraindications, tenofovir (tenofovir disoproxil fumarate) was provided free of charge (Viread [Gilead Sciences, Foster City, CA, USA], 300 mg oral dose once per day). Adherence to treatment was assessed with the Morisky adherence scale. 20
Lemoine M., Shimakawa Y., Njie R., Taal M., Ndow G., Chemin I., Ghosh S., Njai H.F., Jeng A., Sow A., Toure-Kane C., Mboup S., Suso P., Tamba S., Jatta A., Sarr L., Kambi A., Stanger W., Nayagam S., Howell J., Mpabanzi L., Nyan O., Corrah T., Whittle H., Taylor-Robinson S.D., D'Alessandro U., Mendy M, & Thursz M.R. (2016). Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. The Lancet. Global health, 4(8).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!